Ferring, Aventis To Pay $4.8M To End Drug Antitrust Suit

Law360, New York (March 6, 2013, 1:51 PM EST) -- Ferring BV and Aventis Pharmaceuticals Inc. have settled for $4.75 million a proposed class' allegations that the companies thwarted generic competition for anti-diuretic drug DDAVP by fraudulently obtaining a patent on it, according to a Tuesday filing in New York federal court.

Under the proposed settlement, which is subject to court approval, Ferring will pay $3.95 million and Sanofi SA unit Aventis is to pay $800,000 to a proposed class of indirect purchasers who brought antitrust claims against the companies, a memorandum filed by the indirect...
To view the full article, register now.